Combination treatment before surgery for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with prostate cancer that has not spread to distant parts of the body and you are scheduled for surgery to remove the prostate.
- Your cancer is considered high-risk based on one or more of these: an MRI or PSMA PET scan shows the tumor is large (stage T2c or higher), your Gleason score is 8 or higher, your PSA level is 20 ng/ml or higher, or the scan shows cancer in nearby lymph nodes.
- You are in good physical condition (able to carry out daily activities without significant limitation).
- Your PSMA PET scan shows a high level of PSMA in the main tumor (SUVmax of 20 or more).
- Your blood counts, kidney, liver, and clotting tests are within acceptable ranges.
- If you could have children, you agree to use effective birth control during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs given before surgery for locally advanced prostate cancer. The goal is to see if giving these drugs first helps shrink the tumor and improves outcomes after surgery.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
This trial tests a combination of drugs given before prostate removal surgery. The goal is to see if this treatment can shrink or slow high-risk prostate cancer.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.